{"title":"选择性CDK4/6抑制剂在实体肿瘤治疗中的应用","authors":"Bai-hong Zhang, Hong-yun Yue","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.06.007","DOIUrl":null,"url":null,"abstract":"Cyclin-dependent kinase (CDK) inhibitors have been approved for the treatment of ER+ /HER2- advanced breast cancer, and preclinical study and clinical trials are under way for multiple solid cancers. CDK4/6 inhibitors have shown good efficacy for human solid cancers, and it′s future development direction are biomarkers, drug resis-tance and combined therapy in the future. \n \n \nKey words: \nNeoplasms; Cyclin-dependent kinases; Therapeutics; Cell cycle","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"54 1","pages":"350-353"},"PeriodicalIF":0.0000,"publicationDate":"2019-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Application of selective CDK4/6 inhibitors in solid cancers therapy\",\"authors\":\"Bai-hong Zhang, Hong-yun Yue\",\"doi\":\"10.3760/CMA.J.ISSN.1673-422X.2019.06.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cyclin-dependent kinase (CDK) inhibitors have been approved for the treatment of ER+ /HER2- advanced breast cancer, and preclinical study and clinical trials are under way for multiple solid cancers. CDK4/6 inhibitors have shown good efficacy for human solid cancers, and it′s future development direction are biomarkers, drug resis-tance and combined therapy in the future. \\n \\n \\nKey words: \\nNeoplasms; Cyclin-dependent kinases; Therapeutics; Cell cycle\",\"PeriodicalId\":16120,\"journal\":{\"name\":\"国际肿瘤学杂志\",\"volume\":\"54 1\",\"pages\":\"350-353\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"国际肿瘤学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.06.007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际肿瘤学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.06.007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Application of selective CDK4/6 inhibitors in solid cancers therapy
Cyclin-dependent kinase (CDK) inhibitors have been approved for the treatment of ER+ /HER2- advanced breast cancer, and preclinical study and clinical trials are under way for multiple solid cancers. CDK4/6 inhibitors have shown good efficacy for human solid cancers, and it′s future development direction are biomarkers, drug resis-tance and combined therapy in the future.
Key words:
Neoplasms; Cyclin-dependent kinases; Therapeutics; Cell cycle
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
